Illumina (ILMN) Stock Looks Cheap On Cash Flow Yet Pricey On Earnings
Illumina stock has delivered a sharp 111.7% gain over the past year, yet valuation checks send mixed signals as an intrinsic value estimate points to meaningful upside while market multiples lean the other way. For investors, that split raises the question of how much of the recent optimism is already reflected in the current US$207.13 share price.
- The 111.7% return over 1 year may indicate a strong rebound in sentiment that can leave less room for error if expectations ease.
- Future growth in gene sequencing demand and Illumina's ability to convert that demand into consistent cash flows can support the investment case, while execution missteps or slower than expected adoption may weigh on the valuation.
- The broader valuation checks show a low value score, with Illumina screening as undervalued on some cash flow based work but more expensive on earnings multiples. This suggests the stock is not a straightforward bargain at current levels.
The issue now is whether Illumina's current price sits closer to the intrinsic value suggested by the Discounted Cash Flow model or to the richer picture implied by earnings based multiples.
Spot opportunities beyond Illumina's rebound by scanning 50 high quality undervalued stocks, which pairs stronger value scores with solid cash flow support.Is Illumina Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model here uses projected free cash flows to estimate what Illumina might be worth today. On this approach, Illumina’s latest twelve month free cash flow is about $942.9 million, and the projections assume growing cash flows rather than a shrinking business. Those future cash flows are then discounted back to today using a 2 Stage Free Cash Flow to Equity framework in $.
That process produces an estimated intrinsic value of about $261 per share, compared with the current $207.13 share price. The model output implies the stock trades at roughly a 20.6% discount to its calculated value. In other words, on this cash flow view Illumina appears attractively priced despite the strong share price rebound.
On this DCF view, Illumina stock currently looks undervalued relative to the cash flows analysts expect it to generate.
Our Discounted Cash Flow (DCF) analysis suggests Illumina is undervalued by 20.6%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.
Has Illumina Run Too Far on Earnings?
The P/E ratio is a useful cross-check for Illumina because it links what you pay today to the company’s current earnings power. Illumina trades on a P/E of about 38.0x, which is slightly above the Life Sciences industry average of roughly 37.3x and above the peer average of about 33.2x.
The more tailored fair P/E ratio for Illumina is estimated at around 26.7x based on factors such as its sector, risk profile and earnings quality. That sits well below the current market multiple, which leaves a clear premium even after allowing for those characteristics. This suggests a market price that already reflects a generous earnings outlook compared with what this framework would indicate.
On this P/E view, Illumina stock appears overvalued because the current earnings multiple stands well above the level implied by its fair ratio and peer benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Illumina Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Illumina pick up where this valuation split leaves off. They spell out which assumptions about Illumina's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today. Each narrative ties a fair value to a specific story about Illumina's potential catalysts and risks, so you can see over time which version of events is closest to what actually happens.
Community views on Illumina are sharply split, with bullish holders leaning into clinical growth and multiomics while bears focus on competitive and regulatory pressure.
Bull case: 10% undervalued
"With the acquisition of SomaLogic and recent product launches in multiomics, Illumina is uniquely positioned to capitalize on the explosive growth in population genomics and multiomic-driven precision medicine..."
Read the full Bull Case to see why Illumina could be undervalued
Bear case: 63% overvalued
"Intensifying competition from established players such as Thermo Fisher and Roche, as well as new entrants leveraging alternative sequencing and diagnostic technologies, threatens to accelerate pricing pressure..."
Read the full Bear Case to see why Illumina could be overvalued
Do you think there's more to the story for Illumina? Head over to our Community to see what others are saying!
The Bottom Line
For Illumina, the split between the Discounted Cash Flow (DCF) intrinsic value and the richer P/E multiple leaves the story finely balanced. The DCF work points to upside if the company delivers the cash flows implied. However, the elevated earnings multiple and low overall value score suggest the market already prices in a favourable growth path. That gap mainly reflects different views on cash flow durability versus what investors are currently willing to pay for earnings. The key question from here is whether Illumina can turn demand for gene sequencing and multiomics into reliable, growing cash flows without the execution setbacks that bears worry about.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com